The synergistic antitumor effect of vorinostat in combination with BRAF inhibitors [199] and the ability of vorinostat to eliminate BRAF inhibitor-resistant and senescent cells was reported in BRAF-mutated melanoma cells [200]. The gene discussed is BRAF; the disease is melanoma.